PR Newswire Clinical TrialsOriginal article
2026 ASCO LBA | Juncell Therapeutics' GC101 TIL Therapy Achieves Primary Endpoint in the Pivotal Phase II Trial for PD-1 Antibody Failed Advanced Melanoma
Phase 2positiveGC101Positive
AI Analysis
Summary
Juncell Therapeutics' GC101 TIL therapy achieved its primary endpoint in a pivotal Phase 2 trial for PD-1 antibody failed advanced melanoma, with results presented at the 2026 ASCO Annual Meeting.
Clinical Trial Data
Phase
Phase 2
Primary Endpoint
Met
Outcome Details
Primary endpoint achieved in pivotal Phase 2 trial
Importance:7/10
Sentiment:
0.85
TIL therapymelanomaASCO 2026Phase 2primary endpoint
Read the original article
Published by PR Newswire Clinical Trials on June 4, 2026 1:52 AM